Eversept Partners LP Takes Position in enGene Holdings Inc. $ENGN

Eversept Partners LP acquired a new stake in shares of enGene Holdings Inc. (NASDAQ:ENGN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 455,835 shares of the company’s stock, valued at approximately $4,116,000.

Other hedge funds have also made changes to their positions in the company. Privium Fund Management B.V. acquired a new position in shares of enGene during the 4th quarter valued at about $3,179,000. Braidwell LP acquired a new position in shares of enGene during the 3rd quarter valued at about $15,479,000. Omega Fund Management LLC increased its holdings in shares of enGene by 66.5% during the 4th quarter. Omega Fund Management LLC now owns 876,357 shares of the company’s stock valued at $7,914,000 after acquiring an additional 350,000 shares during the last quarter. Eventide Asset Management LLC acquired a new position in shares of enGene during the 4th quarter valued at about $8,578,000. Finally, PFS Partners LLC increased its holdings in shares of enGene by 22.2% during the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Stock Performance

ENGN opened at $1.74 on Thursday. The stock’s 50 day moving average price is $4.10 and its two-hundred day moving average price is $7.10. The company has a quick ratio of 11.75, a current ratio of 12.57 and a debt-to-equity ratio of 0.10. enGene Holdings Inc. has a 12-month low of $1.40 and a 12-month high of $12.25. The firm has a market capitalization of $116.56 million, a P/E ratio of -0.80 and a beta of -0.30.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Monday, June 15th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.91. During the same period in the prior year, the company posted $0.51 earnings per share. On average, equities analysts forecast that enGene Holdings Inc. will post -1.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ENGN. Wells Fargo & Company reissued an “equal weight” rating and set a $2.00 price objective (down from $25.00) on shares of enGene in a report on Friday, May 8th. WBB Securities assumed coverage on enGene in a report on Monday, April 13th. They issued a “buy” rating and a $21.50 target price on the stock. Guggenheim lowered enGene from a “buy” rating to a “neutral” rating in a report on Thursday, May 7th. Morgan Stanley lowered enGene to an “underweight” rating and set a $3.00 target price on the stock. in a report on Thursday. Finally, Piper Sandler lowered enGene from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $7.00 to $4.00 in a report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, enGene has a consensus rating of “Hold” and an average price target of $11.05.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.